aibio.space Listings & Compliance Desk
Exchange deficiency and delisting notices, regained compliance, reverse splits, uplistings, ticker changes, Form 25 and Form 15 filings and trading suspensions.
Sources: SEC filings and company press releases, with wires, trade press and court dockets used as leads and confirmed against a filing. The desk follows our editorial standards. 520 stories so far.
Latest stories
- Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal
- Reviva asks stockholders to approve reverse split of up to 1-for-100
- Nasdaq to delist Glucotrack shares after bid price exception ends
- Milestone Pharmaceuticals falls below Nasdaq's $1.00 minimum bid rule
- Nasdaq panel delists OSR Health over $1.00 bid price rule
- aTyr Pharma sets 1-for-40 reverse split, shares trade adjusted from October 29
- CDT Equity seeks votes on reverse splits up to 1-for-1,000 and Astor note shares
- Enlivex gets Nasdaq delisting notice, plans appeal and 1-for-16 reverse split
- GeoVax signs $1,000,000 credit line as five directors make way for lender nominees
- GeoVax stockholders approve reverse split of up to 1-for-25 and warrant share issuance
- Pulmatrix stockholders approve Eos SENOLYTIX merger and a reverse split
- AEON Biopharma seeks approval for a reverse split of up to 1-for-100
- Onconetix sets a 1-for-10 reverse stock split for November 6
- Silexion shareholders back a 1-for-24 reverse split and more authorized shares
- TScan Therapeutics asks stockholders to approve a reverse split of up to one-for-fifty
- Akebia Therapeutics gets Nasdaq bid price notice, has until April 19, 2027
- Citius Oncology gets Nasdaq extension to April 19, 2027 on bid price
- Lunai Bioworks gets Nasdaq delisting notice and plans to leave the exchange
- Medicus Pharma regains Nasdaq $1.00 bid price compliance days after delisting letter
- Nuwellis sets one-for-nine reverse stock split effective October 26
- Azitra to carry out 1-for-10 reverse stock split on October 26
- Enlivex announces 1-for-16 reverse share split effective October 27, 2026
- Alaunos Therapeutics says $350.0 million financing restores Nasdaq equity compliance
- Silexion adjourns vote on 500 million new shares and reverse split to October 26
- Sangamo's Nasdaq delisting becomes final as Chapter 11 case continues
- Mustang Bio gets a second 180-day Nasdaq grace period to fix its bid price
- Mannatech says it regained Nasdaq stockholders' equity compliance
- Immutep Ltd regains Nasdaq bid price compliance after ADS ratio change
- CytoMed Therapeutics gets Nasdaq bid price notice, has until April 5, 2027
- Alaunos Therapeutics gets Nasdaq delisting notice under $2,500,000 stockholders' equity rule
- Artelo Biosciences flags exposure to Nasdaq's new $5,000,000 market value rule
- Biodexa changes ADS ratio to 400 ordinary shares, a one-for-eight reverse ADS split
- NexGel sets a 1-for-20 reverse stock split effective October 12, 2026
- Nasdaq files to remove Aditxt common stock from listing
- Redhill Biopharma gets 180 more days on Nasdaq bid price, to April 5, 2027
- Nasdaq files SEC notice to remove Sangamo Therapeutics stock from listing
- Kyntra Bio gets Nasdaq delisting determination, requests a hearing
- Universe Pharmaceuticals holders approve conditional 10-into-1 share consolidation
- BeyondSpring gets Nasdaq notice after market value falls below $35 million
- Daré Bioscience gets Nasdaq notice for stock below $1.00
aibio